S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
⚡ 2,467% Return on Israeli Laser Company? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
66,000% upside on tiny biotech? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
⚡ 2,467% Return on Israeli Laser Company? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
66,000% upside on tiny biotech? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
⚡ 2,467% Return on Israeli Laser Company? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
66,000% upside on tiny biotech? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
⚡ 2,467% Return on Israeli Laser Company? (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
66,000% upside on tiny biotech? (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?

Bristol-Myers Squibb (BMY) Stock Forecast, Price & News

+0.73 (+1.15%)
(As of 05/31/2023 ET)
Today's Range
50-Day Range
52-Week Range
13.17 million shs
Average Volume
8.14 million shs
Market Capitalization
$135.38 billion
P/E Ratio
Dividend Yield
Price Target

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating
2.40 Rating Score
23.3% Upside
$79.43 Price Target
Short Interest
1.02% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.25mentions of Bristol-Myers Squibb in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$3.38 M Sold Last Quarter
Proj. Earnings Growth
From $8.06 to $8.01 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

139th out of 1,006 stocks

Pharmaceutical Preparations Industry

51st out of 492 stocks

BMY stock logo

About Bristol-Myers Squibb (NYSE:BMY) Stock

The Bristol-Myers Squibb Company is a leading global biopharmaceutical company with a long and impressive history of innovating and developing medicines that improve the lives of patients around the world. Founded in 1887 when William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical Company, the company was initially named Bristol, Myers and Company. Its first nationally recognized product, Sal Hepatica, was released in the 1890s.

Bristol Myers-Squibb offers chemically synthesized drugs and biologics administered through injections or infusions to patients. The company's pharmaceutical portfolio includes a large number of well-known products. BMS's primary research and development sites are in New Jersey, California, Spain, Massachusetts, New York, Belgium, Japan, India and Massachusetts. The company's products sell to wholesalers and distributors around the world.

Bristol Myers-Squibb has a robust pipeline of investigational medicines in its pipeline. In addition, the company has established strategic collaborations and partnerships with various companies, successfully launching new products. These partnerships and investments generate portions of the company's revenue. 

Bristol Myers-Squibb has acquired several companies over the years, including Medarex in 2009, ZymoGenetics in 2010, Inhibitex Inc. in 2012, Amylin Pharmaceuticals in 2012, iPierian in 2014, Flexus Biosciences in 2015, Cardioxyl in 2015, Padlock Therapeutics in 2016, Cormorant Pharmaceuticals in 2017, IFM Therapeutics in 2017, Celgene in 2019, Otezla in 2019, Forbius in 2020, MyoKardia in 2020 and Turning Point Therapeutics in 2022.

In 2005, the company divested individual consumer products and its subsequent consumer products businesses. In December 2014, the company received FDA approval for its cancer drug, Opdivo, used to treat skin cancers that do not respond to drug therapies. In 2019, the company divested its consumer health business, UPSA, to Taisho. 

The company has also faced several scandals, lawsuits and investigations over the years, the biggest of which is the ongoing $1 billion lawsuit from Guatemala for the company's role in a 1940s experiment that infected hundreds with syphilis. In 2001 BMS faced an accounting scandal that resulted in a restatement of revenues from 1999 to 2001. In 2002, BMS faced a lawsuit based on illegally maintaining a monopoly on Taxol, a chemotherapy medication. The former head of the pharma group and the ex-CFO were indicted for federal securities violations in 2005. In July of 2006, an FBI raid on the company's corporate offices revealed that the company took steps to delay the release of a generic version of one of its drugs.  

BMS began a significant restructuring in 2009, focusing on the pharmaceutical business and biologic products, productivity initiatives and cost-cutting. The U.S. attorney forced the company into oversight and appointed a monitor as part of a deferred prosecution agreement. Lou Schmukler joined Bristol-Myers Squibb in 2010 as global product development and design president. 

In 2013, Forbes magazine ranked the company as the drug company of the year. Dr. Giovanni Caforio took the reigns as CEO in 2015. In 2017, reports began to surface that activist investor Carl Icahn took a stake in the company, widely seen as a signal for a potential future takeover. 

As Bristol-Myers Squibb continues to experience success and growth, the company is committed to delivering innovative treatments to patients and staying ahead of the curve in the biopharmaceutical industry. With its focus on research and development and a long and rich history of delivering innovative medicines, BMS offers an excellent long-term investment opportunity.

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock News Headlines

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application (BMY)
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
Doximity is an Overlooked Medical Ecosystem AI Play (BMY)
Doximity Inc. (NASDAQ: DOCS) is a digital professional social network platform for medical practitioners. It’s a medical community networking platform like
This Company Is Solving A Multi-Billion Dollar Problem!
This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding (BMY)
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
See More Headlines
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Company Calendar

Ex-Dividend for 5/1 Dividend
Last Earnings
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$6.33 billion
Pretax Margin


Sales & Book Value

Annual Sales
$46.16 billion
Cash Flow
$12.74 per share
Book Value
$15.18 per share


Outstanding Shares
Free Float
Market Cap
$135.38 billion

Social Links

Key Executives

  • Giovanni CaforioGiovanni Caforio
    Chairman & Chief Executive Officer
  • Christopher S. BoernerChristopher S. Boerner
    Chief Operating Officer & Director
  • David V. ElkinsDavid V. Elkins
    Chief Financial Officer & Executive Vice President
  • Rupert J. VesseyRupert J. Vessey
    Executive VP-Research & Early Development
  • Samit Hirawat
    Chief Medical Officer-Global Drug Development

BMY Stock - Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
View BMY analyst ratings
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price forecast for 2023?

15 Wall Street research analysts have issued 1 year price targets for Bristol-Myers Squibb's stock. Their BMY share price forecasts range from $62.00 to $95.00. On average, they predict the company's share price to reach $79.43 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for BMY
or view top-rated stocks among Wall Street analysts.

How have BMY shares performed in 2023?

Bristol-Myers Squibb's stock was trading at $71.95 at the start of the year. Since then, BMY stock has decreased by 10.4% and is now trading at $64.44.
View the best growth stocks for 2023 here

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 18,920,000 shares, an increase of 5.8% from the April 15th total of 17,880,000 shares. Based on an average daily volume of 7,750,000 shares, the short-interest ratio is presently 2.4 days. Approximately 0.9% of the shares of the company are short sold.
View Bristol-Myers Squibb's Short Interest

When is Bristol-Myers Squibb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our BMY earnings forecast

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) announced its quarterly earnings results on Thursday, April, 27th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.98 by $0.07. The biopharmaceutical company earned $11.34 billion during the quarter, compared to analyst estimates of $11.50 billion. Bristol-Myers Squibb had a net margin of 15.95% and a trailing twelve-month return on equity of 51.75%. Bristol-Myers Squibb's quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.96 EPS.
Read the conference call transcript

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Friday, March 3rd. Stockholders of record on Monday, April 10th will be paid a dividend of $0.57 per share on Monday, May 1st. This represents a $2.28 annualized dividend and a yield of 3.54%. The ex-dividend date of this dividend is Thursday, April 6th.
Read our dividend analysis for BMY

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb (NYSE:BMY) pays an annual dividend of $2.28 per share and currently has a dividend yield of 3.57%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 66.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BMY will have a dividend payout ratio of 28.46% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BMY.

When did Bristol-Myers Squibb's stock split?

Shares of Bristol-Myers Squibb split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $7.95-$8.25 for the period, compared to the consensus EPS estimate of $8.06. The company issued revenue guidance of $47.08 billion-$47.08 billion, compared to the consensus revenue estimate of $46.84 billion.

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb Chief Executive Officer Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.36%), State Street Corp (4.37%), FMR LLC (2.35%), Geode Capital Management LLC (1.85%), Ameriprise Financial Inc. (1.24%) and Deutsche Bank AG (0.92%). Insiders that own company stock include Adam Dubow, Ann Powell, Autenried Paul Von, Christopher S Boerner, David V Elkins, Dinesh C Paliwal, Giovanni Caforio, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Rupert Vessey and Sandra Leung.
View institutional ownership trends

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $64.44.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb (NYSE:BMY) has a market capitalization of $135.38 billion and generates $46.16 billion in revenue each year. The biopharmaceutical company earns $6.33 billion in net income (profit) each year or $3.43 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

The company employs 34,300 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?
The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More
How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The official website for the company is www.bms.com. The biopharmaceutical company can be reached via phone at (212) 546-4000, via email at john.elicker@bms.com, or via fax at 212-546-4020.

This page (NYSE:BMY) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -